Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Trial of EMB-02, a Bi-specific Antibody Against PD-1 and LAG-3, in Patients With Advanced Solid Tumors

NCT04618393 is registered in ClinicalTrials.gov with Shanghai EpimAb Biotherapeutics Co., Ltd. as lead sponsor.

NCT NCT04618393
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04618393 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Trial of EMB-02, a Bi-specific Antibody Against PD-1 and LAG-3, in Patients With Advanced Solid Tumors
Lead sponsor
Shanghai EpimAb Biotherapeutics Co., Ltd.
Phase
Phase 1/2
Overall status
Terminated
Start date
March 11, 2021
Completion date
March 21, 2024
Enrollment
47 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors